Home Depot (HD) Holder Iberiabank Has Boosted Its Stake; Amicus Therapeutics (FOLD) Shareholder Perceptive Advisors Has Lifted Holding by $8.88 Million as Valuation Rose

February 22, 2018 - By Peter Erickson

Joseph Edelman increased its stake in Amicus Therapeutics Inc (FOLD) by 3.42% based on its latest 2017Q3 regulatory filing with the SEC. Perceptive Advisors Llc bought 591,925 shares as the company’s stock rose 23.92% with the market. The hedge fund run by Joseph Edelman held 17.89M shares of the health care company at the end of 2017Q3, valued at $269.76 million, up from 17.30M at the end of the previous reported quarter. Perceptive Advisors Llc who had been investing in Amicus Therapeutics Inc for a number of months, seems to be bullish on the $2.81B market cap company. The stock increased 1.89% or $0.28 during the last trading session, reaching $15.12. About 5.15 million shares traded or 81.89% up from the average. Amicus Therapeutics, Inc. (NASDAQ:FOLD) has risen 12.45% since February 22, 2017 and is uptrending. It has underperformed by 4.25% the S&P500.

Iberiabank Corp increased its stake in Home Depot Inc (HD) by 93.14% based on its latest 2017Q3 regulatory filing with the SEC. Iberiabank Corp bought 10,297 shares as the company’s stock rose 9.30% with the market. The institutional investor held 21,352 shares of the consumer services company at the end of 2017Q3, valued at $3.50 million, up from 11,055 at the end of the previous reported quarter. Iberiabank Corp who had been investing in Home Depot Inc for a number of months, seems to be bullish on the $213.77B market cap company. The stock decreased 1.95% or $3.65 during the last trading session, reaching $183.06. About 7.53M shares traded or 40.08% up from the average. The Home Depot, Inc. (NYSE:HD) has risen 18.65% since February 22, 2017 and is uptrending. It has outperformed by 1.95% the S&P500.

Investors sentiment increased to 2.33 in 2017 Q3. Its up 1.10, from 1.23 in 2017Q2. It is positive, as 16 investors sold FOLD shares while 32 reduced holdings. 52 funds opened positions while 60 raised stakes. 192.70 million shares or 14.18% more from 168.77 million shares in 2017Q2 were reported. Invesco holds 59,142 shares or 0% of its portfolio. 351,089 were reported by Dimensional Fund Advsr Lp. Moreover, First Midwest Bankshares Division has 0.13% invested in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 68,568 shares. Berson Corrado Investment Advisors Ltd Company reported 34,406 shares. Point72 Asset Mngmt Ltd Partnership holds 0.12% or 1.74M shares. Connor Clark & Lunn Inv Mgmt Limited reported 426,589 shares. Strs Ohio accumulated 0% or 6,800 shares. Essex Inv Mgmt Ltd Com, a Massachusetts-based fund reported 160,889 shares. Hanseatic Mgmt Svcs Inc holds 0% in Amicus Therapeutics, Inc. (NASDAQ:FOLD) or 92 shares. Prudential Fincl, a New Jersey-based fund reported 467,900 shares. Amer Century Cos has 86,328 shares. Parallax Volatility Advisers Ltd Partnership owns 132,723 shares for 0% of their portfolio. Tiaa Cref Inv Ltd Com holds 550,188 shares or 0.01% of its portfolio. Franklin Res reported 3.31M shares. State Of Wisconsin Invest Board holds 0% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 105,000 shares.

Since October 12, 2017, it had 0 insider buys, and 16 selling transactions for $11.04 million activity. On Tuesday, January 2 the insider Barth Jay sold $73,559. Another trade for 449,295 shares valued at $6.44 million was sold by Crowley John F. RAAB MICHAEL sold $142,534 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) on Thursday, October 12. Quimi Daphne also sold $117,723 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) on Tuesday, January 2. On Thursday, October 12 Baird William D III sold $570,132 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) or 40,000 shares. HAYDEN DONALD J JR also sold $300,002 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) on Tuesday, January 2.

Among 9 analysts covering Amicus Therapeutics (NASDAQ:FOLD), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. Amicus Therapeutics had 22 analyst reports since August 18, 2015 according to SRatingsIntel. The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) has “Outperform” rating given on Monday, October 5 by Leerink Swann. The firm earned “Buy” rating on Tuesday, July 11 by Cowen & Co. On Monday, October 5 the stock rating was upgraded by Chardan Capital Markets to “Buy”. The firm has “Buy” rating given on Sunday, June 25 by Cowen & Co. On Tuesday, January 24 the stock rating was upgraded by Robert W. Baird to “Outperform”. The firm earned “Outperform” rating on Wednesday, July 12 by Robert W. Baird. The stock has “Buy” rating by Janney Capital on Tuesday, March 8. On Tuesday, September 1 the stock rating was maintained by Cowen & Co with “Buy”. Leerink Swann maintained Amicus Therapeutics, Inc. (NASDAQ:FOLD) rating on Thursday, February 8. Leerink Swann has “Outperform” rating and $24 target. The rating was downgraded by Chardan Capital Markets on Wednesday, September 16 to “Neutral”.

Perceptive Advisors Llc, which manages about $2.09 billion and $2.62 billion US Long portfolio, decreased its stake in Dbv Technologies S A by 15,346 shares to 576,419 shares, valued at $24.46M in 2017Q3, according to the filing. It also reduced its holding in Aveo Pharmaceuticals Inc (NASDAQ:AVEO) by 2.60M shares in the quarter, leaving it with 3.42M shares, and cut its stake in Acelrx Pharmaceuticals Inc (NASDAQ:ACRX).

Among 33 analysts covering The Home Depot Inc. (NYSE:HD), 24 have Buy rating, 0 Sell and 9 Hold. Therefore 73% are positive. The Home Depot Inc. had 112 analyst reports since August 19, 2015 according to SRatingsIntel. As per Friday, September 8, the company rating was maintained by Robert W. Baird. Credit Suisse maintained the stock with “Buy” rating in Wednesday, November 29 report. The stock has “Buy” rating by Stifel Nicolaus on Wednesday, August 16. The firm has “Neutral” rating given on Thursday, May 11 by Atlantic Securities. The stock of The Home Depot, Inc. (NYSE:HD) earned “Buy” rating by RBC Capital Markets on Monday, September 18. Barclays Capital maintained The Home Depot, Inc. (NYSE:HD) rating on Wednesday, August 16. Barclays Capital has “Overweight” rating and $165 target. The stock of The Home Depot, Inc. (NYSE:HD) has “Neutral” rating given on Tuesday, August 18 by Goldman Sachs. The firm has “Outperform” rating by Credit Suisse given on Monday, December 7. The stock has “Buy” rating by RBC Capital Markets on Thursday, December 7. Nomura upgraded the shares of HD in report on Thursday, June 23 to “Buy” rating.

Since September 7, 2017, it had 0 insider buys, and 3 selling transactions for $14.57 million activity. 10,916 shares were sold by Roseborough Teresa Wynn, worth $1.97 million.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>